Globus Medical (GMED) Cost of Revenue (2011 - 2026)

Globus Medical (GMED) has reported Cost of Revenue for 16 consecutive years, with $241.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 2.94% year-over-year to $241.4 million; the trailing twelve-month figure through Jun 2026 stood at $989.1 million (up 1.13% YoY), and the FY2025 full-year result was $957.8 million, down 7.5% from the prior year.
• Cost of Revenue advanced to $241.4 million in Q2 2026 per GMED's latest filing, from $234.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $270.5 million in Q3 2024 and bottomed at $59.2 million in Q1 2022.
• Historically, Cost of Revenue has averaged $182.3 million across 5 years, with a median of $237.8 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue jumped 276.09% in 2023, then fell 19.09% in 2025.
• Over 5 years, Cost of Revenue stood at $70.6 million in 2022, then surged by 276.09% to $265.5 million in 2023, then dropped by 0.77% to $263.4 million in 2024, then retreated by 0.88% to $261.1 million in 2025, then retreated by 7.53% to $241.4 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $241.4 million, $234.1 million, and $261.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.